Future-gazing radioligand therapy in prostate cancer | With Oliver Sartor and Michael Hofman

Поділитися
Вставка
  • Опубліковано 3 лют 2025

КОМЕНТАРІ • 2

  • @kathleenbullock7677
    @kathleenbullock7677 День тому +1

    And the hospital , in turn, charges my medical insurance $113,000 per dose. Approximately 21:45

  • @doctornebula
    @doctornebula День тому +1

    I love your show and these pioneering physicians but the questions were incredibly softball. I know the topic was the future of RLT, but a brief summary of outcomes of VISION, TheraP, and PSMAfore should have been mentioned. Such as there was no real difference in OS between treatment and control arms in both PSMAfore and TheraP. And why crossover was used in the VISION trial when that confounds OS. They should have been questioned about using an ARPI switch in both VISION and PSMAfore. Please have them back to discuss these concerning issues.